The Cholesterol Paradox Revisited: Heart Failure, Systemic Inflammation, and Beyond

Cowie, 1997, The epidemiology of heart failure, Eur Heart J, 18, 208, 10.1093/oxfordjournals.eurheartj.a015223 Davies, 2001, Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study, Lancet, 358, 439, 10.1016/S0140-6736(01)05620-3 Hunt, 2001, J Am Coll Cardiol, 38, 2101, 10.1016/S0735-1097(01)01683-7 Meerding, 1998, Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study, BMJ, 317, 111, 10.1136/bmj.317.7151.111 O'Connell, 1994, Economic impact of heart failure in the United States: time for a different approach, J Heart Lung Transplant, 13, S107 McMurray, 2000, Epidemiology, aetiology, and prognosis of heart failure, Heart, 83, 596, 10.1136/heart.83.5.596 Remme, 2005, Public awareness of heart failure in Europe: first results from SHAPE, Eur Heart J, 26, 2413, 10.1093/eurheartj/ehi447 Stewart, 2001, More malignant than cancer? Five-year survival following a first admission for heart failure, Eur J Heart Fail, 22, 315, 10.1016/S1388-9842(00)00141-0 Remme, 2001, Guidelines for the diagnosis and treatment of chronic heart failure, Eur Heart J, 22, 1527, 10.1053/euhj.2001.2783 Lloyd-Jones, 2004, Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, Circulation, 110, 1042, 10.1161/01.CIR.0000140263.20897.42 Rosamond, 2008, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 117, e25, 10.1161/CIRCULATIONAHA.107.187998 Anker, 2004, Inflammatory mediators in chronic heart failure: an overview, Heart, 90, 464, 10.1136/hrt.2002.007005 von Haehling, 2002, Cachexia: a therapeutic approach beyond cytokine antagonism, Int J Cardiol, 85, 173, 10.1016/S0167-5273(02)00245-0 Doehner, 2005, Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure, J Am Coll Cardiol, 46, 1019, 10.1016/j.jacc.2005.02.093 Sharma, 2004, Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial, Eur Heart J, 25, 1021, 10.1016/j.ehj.2004.04.023 Komajda, 2006, The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET, Eur Heart J, 27, 1440, 10.1093/eurheartj/ehl012 Witte, 2005, The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure, Eur Heart J, 26, 2238, 10.1093/eurheartj/ehi442 Jankowska, 2006, Autonomic imbalance and immune activation in chronic heart failure: pathophysiological links, Cardiovasc Res, 70, 434, 10.1016/j.cardiores.2006.01.013 Krack, 2005, The importance of the gastrointestinal system in the pathogenesis of heart failure, Eur Heart J, 26, 2368, 10.1093/eurheartj/ehi389 Conraads, 2004, Selective intestinal decontamination in advanced chronic heart failure: a pilot trial, Eur J Heart Fail, 6, 483, 10.1016/j.ejheart.2003.12.004 Sandek, 2007, Altered intestinal function in patients with chronic heart failure, J Am Coll Cardiol, 50, 1561, 10.1016/j.jacc.2007.07.016 Anker, 2002, The syndrome of cardiac cachexia, Int J Cardiol, 85, 51, 10.1016/S0167-5273(02)00233-4 von Haehling, 2007, Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure, Cardiovasc Res, 73, 298, 10.1016/j.cardiores.2006.08.018 Anker, 2002, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH, Int J Cardiol, 86, 123, 10.1016/S0167-5273(02)00470-9 von Haehling, 2004, Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications, Basic Res Cardiol, 99, 18, 10.1007/s00395-003-0433-8 von Haehling, 2005, Future prospects of anticytokine therapy in chronic heart failure, Expert Opin Investig Drugs, 14, 163, 10.1517/13543784.14.2.163 Levine, 1990, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure, N Engl J Med, 323, 236, 10.1056/NEJM199007263230405 Matsumori, 1994, Increased circulating cytokines in patients with myocarditis and cardiomyopathy, Br Heart J, 72, 561, 10.1136/hrt.72.6.561 Tsutamoto, 1998, Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure, J Am Coll Cardiol, 31, 391, 10.1016/S0735-1097(97)00494-4 Genth-Zotz, 2002, Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure, Am J Cardiol, 90, 1226, 10.1016/S0002-9149(02)02839-4 Triantafilou, 2002, Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster, Trends Immunol, 23, 301, 10.1016/S1471-4906(02)02233-0 Földes, 2006, Toll-like receptor modulation in cardiovascular disease: a target for intervention?, Expert Opin Investig Drugs, 15, 857, 10.1517/13543784.15.8.857 da Silva Correia, 2001, Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: transfer from CD14 to TLR4 and MD-2, J Biol Chem, 276, 21129, 10.1074/jbc.M009164200 Shimazu, 1999, MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4, J Exp Med, 189, 1777, 10.1084/jem.189.11.1777 Triantafilou, 2001, A CD14-independent LPS receptor cluster, Nat Immunol, 2, 338, 10.1038/86342 Triantafilou, 2004, Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide, Biochem Soc Trans, 32, 636, 10.1042/BST0320636 Genth-Zotz, 2004, Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival, Int J Cardiol, 96, 397, 10.1016/j.ijcard.2003.08.008 Niebauer, 1999, Endotoxin and immune activation in chronic heart failure: a prospective cohort study, Lancet, 353, 1838, 10.1016/S0140-6736(98)09286-1 Axtelle, 2001, IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis, J Endotoxin Res, 7, 310, 10.1179/096805101101532783 Verbon, 2001, IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans, J Immunol, 166, 3599, 10.4049/jimmunol.166.5.3599 Manocha, 2002, Novel therapies for sepsis: antiendotoxin therapies, Expert Opin Investig Drugs, 11, 1795, 10.1517/13543784.11.12.1795 Rauchhaus, 2003, The relationship between cholesterol and survival in patients with chronic heart failure, J Am Coll Cardiol, 42, 1933, 10.1016/j.jacc.2003.07.016 Horwich, 2002, Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure, J Card Fail, 8, 216, 10.1054/jcaf.2002.0804216 Horwich, 2007, Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS, Semin Dial, 20, 549, 10.1111/j.1525-139X.2007.00346.x Sharma, 2005, Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins, Eur J Heart Fail, 7, 479, 10.1016/j.ejheart.2004.09.013 Gordon, 1996, Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia, Crit Care Med, 24, 584, 10.1097/00003246-199604000-00006 Murch, 2007, Lipoproteins in inflammation and sepsis. I. Basic science, Intensive Care Med, 33, 13, 10.1007/s00134-006-0432-y Wu, 2004, High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications, Shock, 21, 210, 10.1097/01.shk.0000111661.09279.82 Sammalkorpi, 1988, Changes in serum lipoprotein pattern induced by acute infections, Metabolism, 37, 859, 10.1016/0026-0495(88)90120-5 Windler, 1994, The prognostic value of hypocholesterinemia in hospitalized patients, Clin Investig, 72, 939, 10.1007/BF00577732 Chien, 2005, Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis, Crit Care Med, 33, 1688, 10.1097/01.CCM.0000171183.79525.6B van Leeuwen, 2003, Lipoprotein metabolism in patients with severe sepsis, Crit Care Med, 31, 1359, 10.1097/01.CCM.0000059724.08290.51 Rauchhaus, 2000, The endotoxin-lipoprotein hypothesis, Lancet, 356, 930, 10.1016/S0140-6736(00)02690-8 Flegel, 1993, Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I, Infect Immun, 61, 5140, 10.1128/IAI.61.12.5140-5146.1993 Harris, 1990, Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice, J Clin Invest, 86, 696, 10.1172/JCI114765 Levine, 1993, In vivo protection against endotoxin by plasma high density lipoprotein, Proc Natl Acad Sci U S A, 90, 12040, 10.1073/pnas.90.24.12040 Netea, 1998, Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells, Infect Immun, 66, 2365, 10.1128/IAI.66.5.2365-2367.1998 Read, 1995, Triglyceride-rich lipoproteins prevent septic death in rats, J Exp Med, 182, 267, 10.1084/jem.182.1.267 Emancipator, 1992, In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins, Infect Immun, 60, 596, 10.1128/IAI.60.2.596-601.1992 Hubsch, 1995, Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models, J Lab Clin Med, 126, 548 Feingold, 1995, Role for circulating lipoproteins in protection from endotoxin toxicity, Infect Immun, 63, 2041, 10.1128/IAI.63.5.2041-2046.1995 Endo, 1992, The discovery and development of HMG-CoA reductase inhibitors, J Lipid Res, 33, 1569, 10.1016/S0022-2275(20)41379-3 von Haehling, 2004, Statins: a treatment option for chronic heart failure?, Heart Fail Monit, 4, 90 Page, 1997 Shepherd, 1995, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 1998, The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomised controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711 Vaughan, 2000, The evolving role of statins in the management of atherosclerosis, J Am Coll Cardiol, 35, 1, 10.1016/S0735-1097(99)00525-2 von Haehling, 2003, Statins and the role of nitric oxide in chronic heart failure, Heart Fail Rev, 8, 99, 10.1023/A:1022103222857 von Haehling, 2005, Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?, Heart, 91, 1, 10.1136/hrt.2004.042515 Walter, 2004, Effects of statins on endothelium and endothelial progenitor cell recruitment, Semin Vasc Med, 4, 385, 10.1055/s-2004-869595 Aznar, 2001, Rho signals to cell growth and apoptosis, Cancer Lett, 165, 1, 10.1016/S0304-3835(01)00412-8 Anker, 2006, Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients, Int J Cardiol, 112, 234, 10.1016/j.ijcard.2006.03.057 Horwich, 2004, Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure, J Am Coll Cardiol, 43, 642, 10.1016/j.jacc.2003.07.049 Node, 2003, Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy, Circulation, 108, 839, 10.1161/01.CIR.0000084539.58092.DE Sola, 2006, Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure, J Am Coll Cardiol, 47, 332, 10.1016/j.jacc.2005.06.088 Yamada, 2007, Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study, Am Heart J, 153, 1055, 10.1016/j.ahj.2007.03.027 Bleske, 2006, Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level, J Am Coll Cardiol, 47, 338, 10.1016/j.jacc.2005.06.087 Gürgün, 2008, The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure, Int J Cardiol, 123, 102, 10.1016/j.ijcard.2006.11.152 Krum, 2007, Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure, J Card Fail, 13, 1, 10.1016/j.cardfail.2006.09.008 Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201 Döcke, 1997, Monocyte deactivation in septic patients: restoration by IFN-gamma treatment, Nat Med, 3, 678, 10.1038/nm0697-678 Sharma, 2005, Cellular endotoxin desensitization in patients with severe chronic heart failure, Eur J Heart Fail, 7, 865, 10.1016/j.ejheart.2004.09.014 Volk, 1996, Monocyte deactivation-rationale for a new therapeutic strategy in sepsis, Intensive Care Med, 22, S474, 10.1007/BF01743727 von Haehling, 2005, Attenuated specific immunity in chronic heart failure, Eur Heart J, 26, 326 Annane, 2005, Septic shock, Lancet, 365, 63, 10.1016/S0140-6736(04)17667-8 Terblanche, 2007, Statins and sepsis: multiple modifications at multiple levels, Lancet Infect Dis, 7, 358, 10.1016/S1473-3099(07)70111-1 Ando, 2000, Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis, J Pharmacol Exp Ther, 294, 1043 Merx, 2005, Statin treatment after onset of sepsis in a murine model improves survival, Circulation, 112, 117, 10.1161/CIRCULATIONAHA.104.502195 Hackam, 2006, Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis, Lancet, 367, 413, 10.1016/S0140-6736(06)68041-0 Almog, 2004, Prior statin therapy is associated with a decreased rate of severe sepsis, Circulation, 110, 880, 10.1161/01.CIR.0000138932.17956.F1 Majumdar, 2006, Statins and outcomes in patients admitted to hospital and community acquired pneumonia: population based prospective cohort study, BMJ, 333, 999, 10.1136/bmj.38992.565972.7C Martin, 2007, Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation, Pharmacotherapy, 27, 20, 10.1592/phco.27.1.20 van de Garde, 2006, Statin treatment and reduced risk of pneumonia in patients with diabetes, Thorax, 61, 957, 10.1136/thx.2006.062885 Mortensen, 2005, The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia, Respir Res, 25, 82, 10.1186/1465-9921-6-82 Gupta, 2007, Statin use and hospitalization for sepsis in patients with chronic kidney disease, JAMA, 297, 1455, 10.1001/jama.297.13.1455 Thomsen, 2006, Statin use and mortality within 180 days after bacteremia: a population-based cohort study, Crit Care Med, 34, 1080, 10.1097/01.CCM.0000207345.92928.E4 Monneret, 2006, Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock, Intensive Care Med, 32, 1175, 10.1007/s00134-006-0204-8 Reith, 2005, Regulation of MHC class II gene expression by the class II transactivator, Nat Rev Immunol, 5, 793, 10.1038/nri1708 Schefold, 2007, A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a, Shock, 28, 418, 10.1097/shk.0b013e31804f5921 Nierhaus, 2003, Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis, Intensive Care Med, 4, 646, 10.1007/s00134-003-1666-6 1999, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5